Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders.
Ibogaine is a naturally occurring psychoactive alkaloid that has been studied for its potential to treat addiction and other neurological conditions. Silo Pharma's initiative aims to leverage ibogaine's neuroplastic and anti-inflammatory properties to address the unmet medical needs of TBI patients, who often suffer from long-term cognitive and psychiatric impairments. The company plans to conduct preclinical studies and collaborate with research institutions to validate the therapeutic potential of ibogaine-based formulations.
"Traumatic brain injury is a significant public health issue with limited treatment options," said Eric Weisblum, CEO of Silo Pharma, in the press release. "By exploring ibogaine-based therapeutics, we hope to develop novel treatments that can improve outcomes for patients suffering from TBI and related conditions like PTSD."
Silo Pharma's therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The announcement underscores the growing interest in psychedelic-derived compounds for psychiatric and neurological indications. Silo Pharma's move into ibogaine-based therapeutics positions the company at the forefront of this emerging field. The provisional patent application, if granted, would provide intellectual property protection for the company's proprietary formulations and methods.
Investors and stakeholders can find more information about Silo Pharma and its initiatives on the company's website at silopharma.com and in the company's newsroom at https://ibn.fm/SILO. For the full press release, visit https://ibn.fm/HdWHG.
